Ranibizumab treat and extend for neovascular age-related macular degeneration (AMD) - One-year outcomes

被引：0
|
作者：
Trivedi, Dipti [1 ]
Alfaqawi, Fadi [1 ]
Lip, Peck Lin [1 ]
Mushtaq, Bushra [1 ]
Chavan, Randhir [1 ]
机构：
[1] Birmingham & Midland Eye Ctr, Birmingham, W Midlands, England
来源：
EYE | 2018年 / 32卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
RF10
引用
收藏
页码：20 / 23
页数：4
相关论文
共 50 条
  • [1] Infographic: ranibizumab or bevacizumab treat & extend for neovascular age-related macular degeneration (AMD): LUCAS trial
    Barai, Ishani
    Sivaprasad, Sobha
    Henein, Christin
    EYE, 2025, 39 (SUPPL1) : 129 - 131
  • [2] One-year Outcomes of a Treat-and-extend of Ranibizumab for Naive Exudative Age-related Macular Degeneration: Retrospective Analysis
    Choi, Young-Je
    Yoo, Woong-Sun
    Cho, Yong-Wun
    Choi, Yu-Jin
    Chung, In Young
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2021, 62 (07): : 939 - 947
  • [3] Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration
    Ying, Gui-shuang
    Huang, Jiayan
    Maguire, Maureen G.
    Jaffe, Glenn J.
    Grunwald, Juan E.
    Toth, Cynthia
    Daniel, Ebenezer
    Klein, Michael
    Pieramici, Dante
    Wells, John
    Martin, Daniel F.
    OPHTHALMOLOGY, 2013, 120 (01) : 122 - 129
  • [4] Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results
    Pfau, M.
    Fassnacht-Riederle, H. M.
    Freiberg, F. J.
    Wons, J. B.
    Wirth, M.
    Becker, M. D.
    Michels, S.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2016, 233 (08) : 945 - 950
  • [5] One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration
    Yamamoto, Akiko
    Okada, Annabelle A.
    Nakayama, Makiko
    Yoshida, Yumiko
    Kobayashi, Hiroaki
    OPHTHALMOLOGICA, 2017, 237 (03) : 139 - 144
  • [6] Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab
    Abdelfattah, Nizar S.
    Al-Sheikh, Mayss
    Pitetta, Sean
    Mousa, Ahmed
    Sadda, SriniVas R.
    Wykoff, Charles C.
    OPHTHALMOLOGY, 2017, 124 (02) : 215 - 223
  • [7] One-year results of intravitreal aflibercept injections for neovascular age-related macular degeneration using a treat and extend regimen
    Hosokawa, Mio
    Morizane, Yuki
    Kimura, Shuhei
    Shiode, Yusuke
    Doi, Shinichiro
    Hirano, Masayuki
    Fujiwara, Atsushi
    Hosogi, Mika
    Shiraga, Fumio
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [8] Three-year outcomes of a treat and extend regimen of aflibercept for neovascular age-related macular degeneration
    Hosokawa, Mio
    Morizane, Yuki
    Kimura, Shuhei
    Shiode, Yusuke
    Hirano, Masayuki
    Doi, Shinichiro
    Toshima, Shinji
    Takahashi, Kosuke
    Fujiwara, Atsushi
    Kanzaki, Yuki
    Hosogi, Mika
    Shiraga, Fumio
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [9] Three-year Outcomes of Treat and Extend Aflibercept Treatment for Neovascular Age-related Macular Degeneration
    Kataoka, Keiko
    Asai, Keiko
    Tsunekawa, Yuma
    Ito, Yasuki
    Terasaki, Hiroko
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [10] Two-Year Outcomes of "Treat and Extend" Intravitreal Therapy for Neovascular Age-Related Macular Degeneration
    Arnold, Jennifer J.
    Campain, Anna
    Barthelmes, Daniel
    Simpson, Judy M.
    Guymer, Robyn H.
    Hunyor, Alex P.
    McAllister, Ian L.
    Essex, Rohan W.
    Morlet, Nigel
    Gillies, Mark C.
    OPHTHALMOLOGY, 2015, 122 (06) : 1212 - 1219
12345